Identification of expression quantitative trait loci of MTOR associated with the progression of glioma

Huang,Liming; Dai,Lian; Xu,Wenshen; Zhang,Shu; Yan,Danfang; Shi,Xi

doi:10.3892/ol.2017.7319

Identification of expression quantitative trait loci of MTOR associated with the progression of glioma

Authors:
- Liming Huang
- Lian Dai
- Wenshen Xu
- Shu Zhang
- Danfang Yan
- Xi Shi
View Affiliations

Affiliations: The First Department of Chemotherapy, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350005, P.R. China, Department of Medicine, The Third Affiliated People's Hospital, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350108, P.R. China, Department of Laboratory Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350005, P.R. China, Department of Radiation Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: November 1, 2017 https://doi.org/10.3892/ol.2017.7319
Pages: 665-671

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mechanistic target of rapamycin (MTOR) encodes a key modulator of cell growth, proliferation, and apoptosis. Previous studies have demonstrated that the dysregulation of MTOR is involved in the development and progression of several types of cancer, including glioma. In the present study, a comprehensive analysis was conducted to examine whether the expression quantitative trait loci (eQTLs) of MTOR are associated with the progression of glioma. Candidate eQTLs of MTOR were obtained from the Genotype‑Tissue Expression eQTL Browser. The Kaplan‑Meier method and multivariate Cox model were used to analyze the progression‑free survival time of glioma patients. Based on the analysis of 138 glioma patients, one eQTL of MTOR, rs4845964, was demonstrated to be significantly associated with the progression of glioma in a dominant manner. The adjusted hazard ratios (HRs) for patients with the AG or AA genotype at rs4845964 were 2.82 [95% confidence interval (CI), 1.27‑6.27; P=0.0111] and 2.79 (95% CI, 1.10‑7.07; P=0.0312), respectively, compared with those with the GG genotype. When the rs4845964 AG and AA genotypes were combined for analysis, the HR was 2.70 (95% CI, 1.25‑5.82; P=0.0114) vs. the GG genotype. Stratified analyses revealed similar associations between the rs4845964 genotypes and the progression of glioma in all subgroups (following stratification by age, sex and tumor grade). These results demonstrate for the first time that the MTOR eQTL rs4845964 is associated with the progression of glioma.

View Figures

View References

1	Schwartzbaum JA, Fisher JL, Aldape KD and Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2:494–503. 2006. View Article : Google Scholar : PubMed/NCBI
2	Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
3	Siegal T: Clinical impact of molecular biomarkers in gliomas. J Clin Neurosci. 22:437–444. 2015. View Article : Google Scholar : PubMed/NCBI
4	Parker NR, Khong P, Parkinson JF, Howell VM and Wheeler HR: Molecular heterogeneity in glioblastoma: Potential clinical implications. Front Oncol. 5:552015. View Article : Google Scholar : PubMed/NCBI
5	Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell. 149:274–293. 2012. View Article : Google Scholar : PubMed/NCBI
6	Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell. 124:471–484. 2006. View Article : Google Scholar : PubMed/NCBI
7	Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
8	Cheng CK, Fan QW and Weiss WA: PI3K signaling in glioma-animal models and therapeutic challenges. Brain Pathol. 19:112–120. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kubiatowski T, Jang T, Lachyankar MB, Salmonsen R, Nabi RR, Quesenberry PJ, Litofsky NS, Ross AH and Recht LD: Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg. 95:480–488. 2001. View Article : Google Scholar : PubMed/NCBI
10	Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL, Arepalli S, Dillman A, Rafferty IP, Troncoso J, et al: Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 6:e10009522010. View Article : Google Scholar : PubMed/NCBI
11	Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, et al: Mapping the genetic architecture of gene expression in human liver. PLoS Biol. 6:e1072008. View Article : Google Scholar : PubMed/NCBI
12	Montgomery SB, Sammeth M, Gutierrez-Arcelus M, Lach RP, Ingle C, Nisbett J, Guigo R and Dermitzakis ET: Transcriptome genetics using second generation sequencing in a Caucasian population. Nature. 464:773–777. 2010. View Article : Google Scholar : PubMed/NCBI
13	Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME and Cox NJ: Trait-associated SNPs are more likely to be eQTLs: Annotation to enhance discovery from GWAS. PLoS Genet. 6:e10008882010. View Article : Google Scholar : PubMed/NCBI
14	Hulur I, Gamazon ER, Skol AD, Xicola RM, Llor X, Onel K, Ellis NA and Kupfer SS: Enrichment of inflammatory bowel disease and colorectal cancer risk variants in colon expression quantitative trait loci. BMC Genomics. 16:1382015. View Article : Google Scholar : PubMed/NCBI
15	Huang L, Xu W, Yan D, Dai L and Shi X: Identification of expression quantitative trait loci of RPTOR for susceptibility to glioma. Tumour Biol. 37:2305–2311. 2016. View Article : Google Scholar : PubMed/NCBI
16	GTEx Consortium, . The genotype-tissue expression (GTEx) project. Nat Genet. 45:580–585. 2013. View Article : Google Scholar : PubMed/NCBI
17	Hernandez DG, Nalls MA, Moore M, Chong S, Dillman A, Trabzuni D, Gibbs JR, Ryten M, Arepalli S, Weale ME, et al: Integration of GWAS SNPs and tissue specific expression profiling reveal discrete eQTLs for human traits in blood and brain. Neurobiol Dis. 47:20–28. 2012. View Article : Google Scholar : PubMed/NCBI
18	Vigneswaran K, Neill S and Hadjipanayis CG: Beyond the World Health Organization grading of infiltrating gliomas: Advances in the molecular genetics of glioma classification. Ann Transl Med. 3:952015.PubMed/NCBI
19	Fogli A, Chautard E, Vaurs-Barrière C, Pereira B, Müller-Barthélémy M, Court F, Biau J, Pinto AA, Kémény JL, Khalil T, et al: The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival. Carcinogenesis. 37:169–176. 2016. View Article : Google Scholar : PubMed/NCBI
20	de Castro J Vieira, Goncalves CS, Costa S, Linhares P, Vaz R, Nabiço R, Amorim J, Viana-Pereira M, Reis RM and Costa BM: Impact of TGF-β1-509C/T and 869T/C polymorphisms on glioma risk and patient prognosis. Tumour Biol. 36:6525–6532. 2015. View Article : Google Scholar : PubMed/NCBI
21	Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
22	Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M and Holland EC: mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia. 7:356–368. 2005. View Article : Google Scholar : PubMed/NCBI
23	Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, et al: Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 12:3935–3941. 2006. View Article : Google Scholar : PubMed/NCBI
24	Garros-Regulez L, Aldaz P, Arrizabalaga O, Moncho-Amor V, Carrasco-Garcia E, Manterola L, Moreno-Cugnon L, Barrena C, Villanua J, Ruiz I, et al: mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance. Expert Opin Ther Targets. 20:393–405. 2016. View Article : Google Scholar : PubMed/NCBI
25	Wang WJ, Long LM, Yang N, Zhang QQ, Ji WJ, Zhao JH, Qin ZH, Wang Z, Chen G and Liang ZQ: NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol Sin. 34:681–690. 2013. View Article : Google Scholar : PubMed/NCBI
26	Kahn J, Hayman TJ, Jamal M, Rath BH, Kramp T, Camphausen K and Tofilon PJ: The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol. 16:29–37. 2014. View Article : Google Scholar : PubMed/NCBI
27	Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y and Zhao G: NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Cancer Lett. 367:58–68. 2015. View Article : Google Scholar : PubMed/NCBI
28	Nica AC and Dermitzakis ET: Expression quantitative trait loci: Present and future. Philos Trans R Soc Lond B Biol Sci. 368:201203622013. View Article : Google Scholar : PubMed/NCBI
29	Grundberg E, Small KS, Hedman AK, Nica AC, Buil A, Keildson S, Bell JT, Yang TP, Meduri E, Barrett A, et al: Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet. 44:1084–1089. 2012. View Article : Google Scholar : PubMed/NCBI
30	Petretto E, Mangion J, Dickens NJ, Cook SA, Kumaran MK, Lu H, Fischer J, Maatz H, Kren V, Pravenec M, et al: Heritability and tissue specificity of expression quantitative trait loci. PLoS Genet. 2:e1722006. View Article : Google Scholar : PubMed/NCBI